Challenges Of Neuropathic Pain- An Update

NEUROPATHIC PAIN
November 17, 2025 daradia_new 0 Comments

Current Perspectives and Future Directions – Inaugural Lecture of the ISSP Vizag City Branch, Visakhapatnam (9 November 2025)

When a 23-year-old woman develops burning pain, redness, and swelling of her entire hand weeks after a trivial arm injury… when a gentleman with trigeminal neuralgia finds his excruciating electric shocks replaced by relentless burning after radiofrequency… when a 38-year-old IT professional has diffuse back pain, burning, poor sleep, and a “normal” MRI—these are the patients who remind us how complex neuropathic and nociplastic pain truly are. Neuropathic Pain

Neuropathic pain is no longer a niche topic for specialists; it is central to modern pain practice. This blog, adapted from the lecture “The Challenge of Neuropathic Pain: Current Perspectives and Future Directions” by Dr. Gautam Das at Daradia – The Pain Clinic, walks through how to recognize, classify, and manage these difficult conditions—and how to avoid the common traps that lead to years of suffering. Neuropathic Pain

Why Neuropathic Pain Deserves Special Attention

Neuropathic pain affects an estimated 7–10% of the general population, yet less than half achieve satisfactory pain relief with current standard therapies. Neuropathic Pain

The reasons are clear:

  • Phenotypes are heterogeneous – what works for diabetic polyneuropathy may fail completely in postherpetic neuralgia.
  • Mechanisms are complex – peripheral nerve injury, central sensitization, altered descending control, and psychological overlay often co-exist. Neuropathic Pain
  • Societal burden is massive – direct healthcare costs, lost workdays, and diminished quality of life extend far beyond the pain clinic. Neuropathic Pain

To move beyond trial-and-error, we first need a clear language and framework.

Neuropathic vs Nociplastic Pain: Getting the Mechanisms Right

The International Association for the Study of Pain (IASP) provides mechanistic definitions that anchor our diagnostic thinking: Neuropathic Pain

Neuropathic Pain

“Pain arising as a direct consequence of a lesion or disease affecting the somatosensory nervous system.” Neuropathic Pain

  • Peripheral examples: diabetic polyneuropathy, entrapment neuropathy, traumatic nerve injury
  • Central examples: post-stroke pain, spinal cord injury pain

Here, you must be able to demonstrate pathology—structural or functional.

Nociplastic Pain

“Pain arising from altered nociception despite no clear evidence of tissue damage or somatosensory system lesion.” Neuropathic Pain

  • Typical examples: fibromyalgia, non-specific chronic low back pain
  • Features: disproportionate pain, fatigue, sleep disturbance, cognitive symptoms, multiple tender points, poor response to structural interventions Neuropathic Pain

Mixed Phenotypes: The Real-World Reality

Most chronic pain patients do not fit neatly into one category. A person with diabetic neuropathy may also develop central sensitization and widespread nociplastic features. Neuropathic Pain

Clinical pearl: If you don’t look for mixed neuropathic–nociplastic phenotypes, you will keep escalating procedures and medications while treating the wrong mechanism.

How Neuropathic Pain Develops: From Injury to Perception

Neuropathic pain involves disturbance at multiple levels of the neuraxis: Neuropathic Pain

  • Transduction: Peripheral nerve injury → ectopic discharges, inflammatory sensitization of nociceptors
  • Transmission: Disinhibition in the dorsal horn, increased excitability of wide dynamic range neurons
  • Modulation: Failure of descending inhibitory systems (serotonin, norepinephrine)
  • Perception: Cortical reorganisation and limbic involvement alter the emotional and sensory experience of pain

Both peripheral sensitization (sensitized nociceptors) and central sensitization (amplified CNS processing) are usually present. Therapies must therefore be multitarget rather than single-mechanism.

Neuropathic vs Nociplastic: Key Clinical Differences

While there is overlap, some contrasts help guide your working diagnosis: Neuropathic Pain

  • Etiology
    • Neuropathic: clear nerve lesion/disease (diabetes, herpes zoster, compression, trauma)
    • Nociplastic: no demonstrable lesion on routine imaging or nerve conduction studies
  • Clinical signs
    • Neuropathic: focal neurologic deficits (sensory loss, weakness, reflex changes) in a nerve or dermatome
    • Nociplastic: widespread, often bilateral, non-dermatomal sensitivity without objective deficits
  • Investigations
    • Neuropathic: EMG/NCS or imaging often show abnormalities
    • Nociplastic: standard tests usually normal; diagnosis is clinical

Shared ground: both conditions are heavily influenced by central sensitization, sleep and mood disturbances, and require layered biopsychosocial care. Neuropathic Pain

Bedside Phenotyping: From Patient Story to Mechanism

Listening for “Neuropathic” Language

Patients often tell you the mechanism if you let them speak first: Neuropathic Pain

Signal phrases include:

  • “Burning, shooting, electric shock-like pain”
  • “Pins and needles” or “numbness with pain”
  • “Painful to light touch” (allodynia)
  • “Stabbing or lancinating bolts of pain” Neuropathic Pain

Pay attention to:

  • Distribution: map pain to dermatomes or peripheral nerve territories
  • Temporal pattern: constant baseline with paroxysms, especially nocturnal worsening in small fiber neuropathy
  • Associated symptoms: sensory changes, weakness, colour/temperature asymmetry, sweating abnormalities Neuropathic Pain

Screening Tools: Making the Invisible Visible

Simple questionnaires help quantify neuropathic features and standardize your assessment: Neuropathic Pain

  • DN4
  • painDETECT (also grades mixed pain) Neuropathic Pain
  • LANSS
  • ID-Pain

Choose one tool and use it consistently—both for detection and tracking response over time. Neuropathic Pain

Focused Neurological Examination

A targeted exam is usually enough: Neuropathic Pain

  1. Sensory mapping – light touch, pinprick, temperature, vibration; document hypoesthesia, hyperalgesia, allodynia
  2. Motor and reflexes – look for weakness, asymmetrical reflex loss, atrophy
  3. Autonomic signs – especially in suspected CRPS: colour changes, temperature asymmetry, sweating, trophic changes

Role of Investigations

Use electrodiagnostics and imaging only when results will change management: Neuropathic Pain

  • EMG/NCS: grading severity, localizing lesions, differentiating axonal vs demyelinating pathology
  • Imaging: MRI for compressive lesions, CT for planning procedures

Remember: normal tests do not exclude small-fiber neuropathy or nociplastic pain.

Common Neuropathic Pain Syndromes in Practice

Neuropathic mechanisms are shared, but each syndrome has distinct nuances: Neuropathic Pain

  • Diabetic polyneuropathy (DPN) – “burning feet,” length-dependent sensory loss; foot care and metabolic control are essential, with SNRIs and gabapentinoids as pillars of treatment. Neuropathic Pain
  • Postherpetic neuralgia (PHN) – dermatomal pain after shingles; topical therapies and gabapentinoids/TCAs are mainstays, with vaccination crucial for prevention. Neuropathic Pain
  • Radiculopathy – unilateral dermatomal pain from root compression; most cases improve with conservative care, with epidural injections or surgery reserved for persistent or progressive deficits. Neuropathic Pain
  • Entrapment neuropathies – carpal tunnel, cubital tunnel, meralgia paresthetica, etc.; activity modification, splinting, hydrodissection, and, when needed, surgical decompression. Neuropathic Pain
  • Post-surgical neuropathic pain & FBSS – early recognition and realistic expectations are key; neuromodulation is increasingly used in carefully selected patients. Neuropathic Pain
  • Complex regional pain syndrome (CRPS) – disproportionate pain with autonomic and trophic changes; early functional restoration is the core of management, with sympathetic blocks and neuromodulation as adjuncts. Neuropathic Pain

Treatment Philosophy: From Guidelines to Real Patients

Effective neuropathic pain management is not about endlessly adding drugs and procedures. It is about rational escalation: Neuropathic Pain

  1. Phenotype accurately – neuropathic, nociplastic, or mixed?
  2. Start with evidence-based basics – pharmacotherapy + non-pharmacological care
  3. Add interventions when indicated – diagnosis-driven, not symptom-driven
  4. Reassess and de-escalate – stop what doesn’t help

First-Line Pharmacotherapy

International guidelines converge on three first-line drug classes: Neuropathic Pain

  • SNRIs – duloxetine, venlafaxine
  • Gabapentinoids – pregabalin, gabapentin
  • TCAs – amitriptyline, nortriptyline

Key principles:

  • Start low, titrate slowly every 3–7 days
  • Allow 2–4 weeks at target dose before judging efficacy
  • Match drug choice to comorbidities (e.g., depression, insomnia, cardiac disease) Neuropathic Pain

Second-Line Options

When first-line therapy is insufficient or poorly tolerated: Neuropathic Pain

  • Topical lidocaine 5% patches – especially in PHN and focal allodynia
  • Capsaicin 8% patches – in-office application; useful for PHN and HIV neuropathy
  • Vitamin B12 and alpha-lipoic acid – consider in documented deficiencies or high-risk groups
  • Rational combinations – e.g., TCA + gabapentinoid

Third-Line and Conditional Therapies

Reserved for refractory cases: Neuropathic Pain

  • Tramadol / other opioids – short-term, lowest effective dose, careful monitoring
  • Lidocaine or ketamine infusions – in select refractory CRPS or PHN
  • Cannabinoids – guideline positions vary; generally considered late-line

Non-Pharmacological Core: The Foundation of Long-Term Success

Drugs and procedures are only part of the story. A stable, long-term plan always rests on: Neuropathic Pain

  • Patient education – explaining mechanisms and setting realistic goals (reduction, not elimination, of pain)
  • Sleep hygiene and mood management – CBT-I, depression/anxiety screening, early psychiatric collaboration
  • Graded activity and desensitisation – to break the cycle of fear-avoidance and deconditioning
  • Cognitive-behavioural and multidisciplinary approaches – CBT, ACT, and comprehensive pain programs for complex cases

Interventional Procedures: Powerful Tools, Not Magic Bullets

Interventions have diagnostic, therapeutic, and neuromodulatory roles—but must be embedded in a wider plan. Neuropathic Pain

Epidural Steroid Injections (ESI) for Radiculopathy

  • Transforaminal, interlaminar, or caudal routes chosen based on pathology and anatomy
  • Provide short- to intermediate-term relief (up to ~3 months) with modest effect sizes
  • Best used to facilitate physiotherapy and functional restoration, not as stand-alone cures Neuropathic Pain

Sympathetic Blocks in CRPS

  • Stellate ganglion (upper limb) and lumbar sympathetic blocks (lower limb) can temporarily reduce sympathetically-maintained pain
  • Series of blocks may help, but should be seen as adjuncts that enable aggressive rehabilitation, not as definitive therapies Neuropathic Pain

Radiofrequency (RF) Techniques

  • Conventional RF (neurotomy) – thermal lesioning, particularly for facet-mediated axial pain
  • Pulsed RF (PRF) – neuromodulatory, non-ablative; used at dorsal root ganglion or peripheral nerves in selected neuropathic conditions Neuropathic Pain

Evidence is evolving; outcomes are best when RF is integrated into a multimodal programme rather than used in isolation.

Neuromodulation

  • Spinal cord stimulation (SCS) – for FBSS, CRPS, refractory DPN
  • Dorsal root ganglion (DRG) stimulation – for focal, dermatomal pain
  • Peripheral nerve stimulation (PNS) – for mononeuropathies, occipital neuralgia, localized post-surgical pain Neuropathic Pain

These technologies are expensive and invasive, and should be considered only after thorough conservative management, psychological screening, and a successful trial period.

Regenerative Medicine: Promise with Caution

Platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and mesenchymal stem cells (MSCs) generate enormous interest among patients and clinicians alike. Neuropathic Pain

Current realities:

  • Early studies and case series show possible benefit in some entrapment neuropathies (e.g., carpal tunnel)
  • Protocols vary widely; high-quality randomized trials are still limited
  • Costs are high, and long-term safety/efficacy data are sparse

Ethical obligation: be honest about the experimental nature, lack of robust long-term evidence, and financial implications. Avoid overpromising.

Nociplastic Overlay: When Procedures Keep Failing

One of the most important skills in modern pain medicine is recognising when nociplastic factors dominate a neuropathic presentation: Neuropathic Pain

Clinical clues:

  • Pain distribution exceeds anatomical boundaries
  • Multiple “failed” interventions and drug trials
  • Prominent sleep and mood disturbances
  • High opioid doses with limited benefit
  • Catastrophizing and fear-avoidance behaviour

In such cases, the strategy must shift away from procedure cascades towards central sensitisation and biopsychosocial management—treating sleep, mood, deconditioning, and maladaptive beliefs as primary targets.

A Practical Treatment Algorithm

Dr. Das’ lecture concludes with a pragmatic algorithm that can be adapted to almost any clinic: Neuropathic Pain

  1. Phenotype
    • Classify as predominantly neuropathic, nociplastic, or mixed
    • Identify syndrome (DPN, PHN, radiculopathy, entrapment, CRPS, FBSS, etc.)
    • Assess psychosocial context
  2. Initiate guideline-consistent pharmacotherapy + non-pharm
    • Choose first-line drug based on comorbidities and patient preference
    • Simultaneously begin education, graded activity, sleep and mood management
  3. Assess response
    • Give 2–4 weeks at target dose
    • Optimize dose, switch, or combine as appropriate
  4. Add interventions as indicated
    • ESI for persistent radiculopathy
    • Targeted nerve blocks, PRF, or neuromodulation for refractory focal pain
    • Always integrate with rehab and self-management
  5. Reassess and de-escalate
    • Stop ineffective therapies
    • Reconsider diagnosis (especially nociplastic overlay)
    • Avoid therapeutic inertia

Measuring What Really Matters

A “successful” neuropathic pain treatment is not just a lower pain score—it is a life reclaimed. Outcome assessment should therefore be multidimensional: Neuropathic Pain

  • Pain intensity and interference (e.g., Brief Pain Inventory)
  • Sleep quality (PSQI), mood (PHQ-9, GAD-7)
  • Patient-defined functional goals (“walk 20 minutes”, “sleep through the night”, “return to work part-time”)

Regularly audit the regimen and de-prescribe what is not helping.

Looking Ahead: The Future of Neuropathic Pain Management

The coming decade is likely to bring: Neuropathic Pain

  • Better phenotype-to-therapy matching using sensory profiles and quantitative sensory testing
  • Biomarkers of neuroinflammation and central sensitization
  • Advancements in central imaging to guide neuromodulation
  • Closed-loop neuromodulation systems and non-invasive brain stimulation
  • Rigorous regenerative medicine trials with standardized protocols

Until then, the most powerful tools we have are careful listening, mechanism-based thinking, guideline-consistent therapy, and a truly multidisciplinary approach.

Key Take-Home Messages

  • Always screen for mixed neuropathic–nociplastic phenotypes rather than forcing patients into a single box. Neuropathic Pain
  • Start with basics done well—education, sleep and mood management, graded activity, and first-line pharmacotherapy—before escalating to invasive options. Neuropathic Pain
  • Track outcomes across multiple domains and stop what doesn’t help, instead of accumulating drugs and procedures indefinitely. Neuropathic Pain

Neuropathic pain will always be challenging—but with structured assessment, mechanism-based treatment, and disciplined reassessment, we can move many patients from “nothing works for me” to “my life is mine again.”

See the presentatio below with DOI: 10.5281/zenodo.17628609

This lecture was presented at a seminar during the inauguration of the Visag city branch.

author avatar
daradia_new
See Full Bio